$10.62
0.66%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US01626L1052
Symbol
ALGS

Aligos Therapeutics Inc Stock price

$10.62
+2.62 32.75% 1M
-3.88 26.76% 6M
-29.22 73.34% YTD
-2.06 16.25% 1Y
-19.88 65.18% 3Y
-364.38 97.17% 5Y
-364.38 97.17% 10Y
-364.38 97.17% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.07 0.66%
ISIN
US01626L1052
Symbol
ALGS
Industry

Key metrics

Basic
Market capitalization
$65.3m
Enterprise Value
$-57.5m
Net debt
positive
Cash
$123.0m
Shares outstanding
7.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
20.6 | 29.1
EV/Sales
negative | negative
EV/FCF
0.8
P/B
0.6
Financial Health
Equity Ratio
-41.3%
Return on Equity
452.9%
ROCE
-68.6%
ROIC
-1,756.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.2m | $2.2m
EBITDA
$-77.6m | -
EBIT
$-78.5m | $-91.0m
Net Income
$-74.2m | $-60.9m
Free Cash Flow
$-75.1m
Growth (TTM | estimate)
Revenue
-60.2% | -43.2%
EBITDA
16.0% | -
EBIT
16.1% | -7.2%
Net Income
2.0% | 53.6%
Free Cash Flow
12.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,443.7% | -
EBIT
-2,473.4%
Net
-2,337.2% | -2,715.2%
Free Cash Flow
-2,366.8%
More
EPS
$-7.2
FCF per Share
$-10.8
Short interest
5.0%
Employees
70
Rev per Employee
$60.0k
Show more

Is Aligos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Aligos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Aligos Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Aligos Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Aligos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3.17 3.17
60% 60%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
37% 37%
511%
- Research and Development Expense 61 61
19% 19%
1,933%
-78 -78
16% 16%
-2,447%
- Depreciation and Amortization 0.94 0.94
24% 24%
30%
EBIT (Operating Income) EBIT -79 -79
16% 16%
-2,476%
Net Profit -74 -74
2% 2%
-2,340%

In millions USD.

Don't miss a Thing! We will send you all news about Aligos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aligos Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 17 hours ago
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.
Neutral
GlobeNewsWire
14 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately.
Neutral
GlobeNewsWire
19 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purc...
More Aligos Therapeutics Inc News

Company Profile

Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lawrence Blatt
Employees 70
Founded 2018
Website www.aligos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today